[News Brief] NeuroSense Reports Phase 2 Biomarker Findings for PrimeC
NeuroSense Therapeutics has reported biomarker findings from its Phase 2 RoAD proof-of-concept study evaluating PrimeC in patients with Alzheimer’s disease.
- Study Findings: The study reported changes across multiple biomarkers associated with neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement.
- Study Design: The RoAD study was a randomised, double-blind, placebo-controlled exploratory trial evaluating the safety, tolerability and biomarker effects of PrimeC in eight participants with Alzheimer’s disease.
- Next Steps: NeuroSense intends to use the findings to inform the design of a future adequately powered clinical study of PrimeC in Alzheimer’s disease.
This summary is based on a news report published by BioSpectrum Asia.
Image for illustrative purposes only. Source: Canva.
About Ehub365
For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news.
A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.
